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Summary
Aims/Hypothesis: Our aim was to quantify the impact of Blood Glucose Monitoring 
Strips variability (BGMSV) at GP practice level on the variability of reported glycated 
haemoglobin	(HbA1cV)	levels.
Methods:	Overall	GP	Practice	BGMSV	and	HbA1cV	were	calculated	from	the	quan-
tity of main types of BGMS being prescribed combined with the published accuracy, 
as % results within ±% bands from reference value for the selected strip type. The 
regression	coefficient	between	the	BGMSV	and	HbA1cV	was	calculated.	To	allow	for	
the aggregation of estimated three tests/day over 13 weeks (ie, 300 samples) of ac-
tual	Blood	Glucose	(BG)	values	up	to	the	HbA1c,	we	multiplied	HbA1cV	coefficient	
by	√300	to	estimate	an	empirical	value	for	impact	of	BGMSV	on	BGV.
Results: Four thousand five hundred and twenty- four practice years with 159 700 
T1DM patient years where accuracy data were available for more than 80% of strips 
prescribed	were	included,	with	overall	BGMSV	6.5%	and	HbA1c	mean	of	66.9	mmol/
mol	(8.3%)	with	variability	of	13	mmol/mol	equal	to	19%	of	the	mean.	At	a	GP	prac-
tice	level,	BGMSV	and	HbA1cV	as	%	of	mean	HbA1c	(in	other	words,	the	spread	of	
HbA1c)	were	closely	related	with	a	regression	coefficient	of	0.176,	P < 0.001. Thus, 
greater variability in the BGMS at a GP practice level resulted in a greater spread of 
HbA1C	readings	in	T1DM	patients.	Applying	this	factor	for	BGMS	to	the	national	ISO	
accepted	standard	where	95%	results	must	be	≤±15%	from	reference,	revealed	that	
for	BG,	95%	results	would	be	≤±45%	from	the	reference	value.	Thus,	the	variation	in	
BG	is	three	times	that	of	the	BGMS.	For	a	patient	with	BG	target	@10	mmol/L	using	
the worst performing ISO standard strips, on 1/20 occasions (average 1/week) actual 
blood	 glucose	 value	 could	 be	>±4.5	mmol/L	 from	 target,	 compared	with	 the	 best	
performing	BGMS	with	BG	>±2.2	mmol/L	from	reference	on	1/20	occasions.
Conclusion: Use of more variable/less accurate BGMS is associated both theoreti-
cally	and	in	practice	with	a	larger	variability	in	measured	BG	and	HbA1c,	with	implica-
tions	for	patient	confidence	in	their	day-	to-	day	monitoring	experience.
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution-NonCommercial	License,	which	permits	use,	distribution	and	reproduction	
in any medium, provided the original work is properly cited and is not used for commercial purposes.
©	2018	The	Authors.	International Journal of Clinical Practice	published	by	John	Wiley	&	Sons	Ltd.
2 of 9  |     HEALD Et AL.
1  | INTRODUC TION
Accessible	 blood	 glucose	 monitoring	 (BGM)	 has	 been	 part	 of	 the	
management of diabetes mellitus, since 1981 with the launch of 
the ®Glucometer. The technology was initially applied to patients 
treated with insulin and more recently used by type 2 diabetes 
(T2DM) patients on oral hypoglycaemic agents, particularly the in-
sulin secretagogues.
One measure of the accuracy of blood glucose monitoring sys-
tems is to establish the % of deviation of the measured value from 
the value measured by a reference analytical method that is needed 
to contain 95% of samples tested.
An	“In	Silico	Study”	by	Breton	and	Kovatchev	 in	20101 applied 
BGM systems of increasing accuracy to establish the link to varia-
tions	in	actual	levels	of	blood	glucose.	A	derivative	analysis	of	their	
results showed that the level of variation in blood glucose was 2.4 
times higher than the level of accuracy in the BGM systems (Table 1).
They showed that improved accuracy would reduce risk of 
both short- term hypoglycaemic events and sustained periods of 
hyperglycaemia.
A	 patient’s	 glycated	 haemoglobin	 (HbA1c)	 result	 captures	 an	
average blood glucose over previous 13 weeks and is now the cor-
nerstone	of	diabetes	management.	However,	this	single	result	on	its	
own cannot capture the shorter term glycaemic variation (GV) that 
is a result of less accurate BGM systems. Since type 1 diabetes pa-
tients measure and adjust their insulin dose up to 10 or more times/
day,	one	element	of	the	standard	deviation	in	their	HbA1c	could	be	
the standard deviation in blood glucose accuracy.
Previously, the standard for blood glucose monitoring systems 
was	that	95%	of	results	for	samples	with	blood	glucose	>4.2	mmol/L	
(75	mg/dL)	should	be	±	20%	from	the	reference	value.	But	in	2013,	
an updated set of standards (ISO: 15197:2013)2 was published speci-
fying	that	for	blood	glucose	>5.6	mmol/L	(100	mg/dL)	95%	of	results	
should be ± 15%.
In the UK, the Greater Manchester Medicines Group3 evaluated 
the provider strips data and reported their compliance (Table 2) with 
the new standard.
The	 interaction	between	BGM	performance	and	patient	expe-
rience of their self- diabetes management4,5 illustrates how we may 
be able to improve further the metabolic control of the patients who 
use BGM strips.
The	aim	of	this	study	was	to	see	if	the	accuracy	of	the	mix	of	strips	
used	within	 each	 practice	may	 be	 related	 to	 the	 spread	 of	HbA1c	
control being achieved for type 1 diabetes patients (T1DM) within 
that practice and if so whether that level of correlation was similar to 
the	level	of	correlation	in	blood	glucose	identified	earlier	“in	silico”.
2  | METHODOLOGY
The	National	Health	Service	(NHS)	publishes	at	GP	practice	level	in	
the	National	Diabetes	Audit	(NDA)6	the	spread	of	HbA1C	(%	patients	
≤48	mmol/mol	 (6.5%),	%	patients	 ≤58	mmol/mol	 (7.5%)	 and	%	pa-
tients	≤86	mmol/mol	(10%))	and	in	GP	prescribing	data	the	number	
of	each	types	of	BGM	strips	being	prescribed.	Accuracy	data	for	the	
various prescribed BGM strips are published in the scientific litera-
ture as % results >20%, >15%, >10%, >5% from the reference value.
The	original	complete	patient	 level	HbA1c	and	BGM	strip	 level	
accuracy datasets were not available to us. Published results for 
What’s known about this subject?
•	 Accessible	 blood	 glucose	 monitoring	 (BGM)	 has	 been	
part of diabetes mellitus (DM) management since 1981.
• One measure of the accuracy of BGM systems is to es-
tablish the statistical values for each type of strip of % 
deviation of the measured value from the value meas-
ured by a reference analytical method.
What is the key question?
•	 To	determine	how	accuracy	of	the	mix	of	BGM	strips	used	
within	each	GP	practice	may	relate	to	the	spread	of	HbA1c	
for type 1 diabetes (T1DM) patients at GP practice level.
What are the new findings?
• The key finding is the linear relation between GP prac-
tice level lower prescribed strip accuracy (lower per-
centage of readings within 10% of the reference 
laboratory blood glucose) and increased variability in 
HbA1C	for	T1DM	individuals.
• For a patient with BG target @10 mmol/l using standard 
BGM strips, on 1/20 occasions (average 1/week), their 
actual blood glucose value could be >±4.5 mmol/l from 
target, compared with the best performing BGMS with 
BG >±2.2 mmol/l from reference on 1/20 occasions.
How might this impact clinical practice in the fore-
seeable future?
• In the short term, use of less accurate BGM strips will 
contribute to unstable glycaemia for T1DM individuals 
and in the longer term could increase the development 
of diabetes complications. We suggest there are clear 
advantages to utilising best in class accuracy BGMS.
TABLE  1 Relationship between BGM meter accuracy and 
expected	Blood	Glucose	taken	from	Breton	and	Kovatchev	(2010)
BGM Meter 95% results ±
@ 100 mg/dL blood glucose 
95% results within ±
5% 12 mg/dl
10% 24 mg/dl
15% 39 mg/dl
20% 47 mg/dl
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both	 HbA1c	 and	 BGMS	 are	 shown	 as	 %	 of	 results	 falling	 within	
given	bands.	We	calculated	a	“variability”	measure	within	each	prac-
tice in each year using methodology principles similar to standard 
deviation.
We conducted the analysis in the following way:
1. Considered the available GP practice level National Diabetes 
Audit	 for	 type	 1	 data	 over	 a	 period	 of	 3	years	 (2013_14,	
2014_15,	 2015_16)	 in	 England.
2. Calculated	 from	%	HbA1c	 results	 in	 each	band	 (≤48	mmol/mol	
(6.5%), 48-58 mmol/mol (6.5%-7.5%), 58-86 mmol/mol (7.5%-
10%)and	>86	mmol/mol	(>10%))	an	estimated	mean	and	“variabil-
ity”	of	HbA1c	in	each	practice.
3. Consolidated the values taken from the various published sci-
entific reports to generate an overall average published % of 
strips falling in each band (<5%, 5%-10%, 10%-15%, 15-20% 
and >20%), for the 40 main types of blood glucose strips. To 
reduce the measurement methodology variation, the sources 
of BGMS accuracy data were restricted to three papers with 
similar methodology covering 20 strip types, 73% of the strips 
being prescribed and only taking results for strips tested since 
2011.7-9
4. This was then weighted by the total number of strips of each type 
prescribed in each practice in that year to calculate the average 
percentage in each accuracy band in that practice and from this 
the	annual	“variability”	of	BGMS	accuracy	for	that	practice	was	
calculated.
5. Calculated the level of correlation between the practice BGMS 
and	HbA1c	variability.
6. Assumed	that	since	HbA1c	is	a	measure	of	the	average	blood	glu-
cose over 3 months, and during that period there would be around 
three	 interventions/day	 to	 adjust	 blood	 sugar,	 each	 HbA1c	 re-
flects an average of over 300 samples. With a normal distribution, 
the	standard	deviation	of	HbA1c	can	be	multiplied	by	the	square	
root of number of samples 17.3 to establish the standard devia-
tion in the actual blood glucose.
F IGURE  1 Flow chart describing GP practice selection
TOTALQOF register
Practice years: 23 319
Total practice patient lists: 170 691 951 7,320/practice year
Diabetes QOF register patient years: 8 761 071 5.1% with Diabetes
Estim. patient years on insulin (@50 u/d): 2 629 100 113/practice year
Estim. patients years BGM strips (@3 strips/d): 1 695 282 73/practice year
Non participating:Participated in NDA:
Practice years: 14 523 62% of total 8 796 38% of total
Total practice patient lists: 112 476 795 7 745/practice year 58 215 156 6 618/practice year
Diabetes QOF register patient years: 5 754 556 5.1% with Diabetes 3 006 515 5.2%with Diabetes
NDA type 1 register 447 577 7.8% of which with T1
31/practice yearT1 patients:
Estim. patient years on insulin (@50 u/d): 1 725 715 119/practice year 903 386 103/practice year
Estim. patients years BGM strips (@3 strips/d): 1 123 585 77/practice year 571 696 65/practice year
Outcome % T1 patients with HbA1c >86 mmol/mol 15.4%
WITH >10 T1 Patients: =HTIW <10 T1 Patients:
Practice years: 12 660 87% of participating 1 863 13% of participating
Total practice patient lists: 106 811 912 8 437/practice 5 664 883 3 041/practice
Diabetes QOF register patient years: 5 423 710 5.1% with Diabetes 330 846 5.8% with Diabetes
NDA type 1 register 434 675 8.0% of which with T1 12 902 3.9% of which with T1
7/practice34/practiceT1 patients
Estim. patient years on insulin (@50 u/d): 1 643 962 130/practice 81 752 44/practice
Estim. patients years BGM strips (@3 strips/d): 1 075 582 85/practice 48 004 26/practice
Outcome % T1 patients with HbA1c >86 mmol/mol 15.3% 17.7%
With ≥80% of strips with Accuracy Data With <80% Strips with Accuracy data
Practice years: 4 525 36% of larger 8 135 64% of larger
Total practice patient lists: 37 997 084 8 397/practice 68 814 828 8 459/practice
Diabetes QOF register patient years: 1 981 465 5.2% with Diabetes 3 442 245 5.0% with Diabetes
NDA type 1 register 159 585 8.1% of which with T1 275 090 8.0% of which with T1
34/practice35/practiceT1 patients
Estim. patient years on Insulin (@50 u/d): 607 751 134/practice 1 036 211 127/practice
Estim. patients years BGM strips (@3 strips/d): 395 810 87/practice 679 771 84/practice
Outcome % T1 patients with HbA1c >86 mmol/mol 15.6% 15.1%
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7. Compared this empirical measured correlation factor to the 
Breton1 in silico-based calculated factor.
8. Considered what this factor might mean to patients when using 
either ISO Standard or best in class strips.
The	restrictions	&	assumptions	were	as	follows:
•	 Accuracy	 varies	 by	 strip	 and	meter	 and	 changes	 over	 time	 and	
there is no central register of strip accuracies
•	 We	were	 looking	at	T1DM.	However,	both	 insulin	and	BGMS	
are used for some T2DM patients and types of strips may 
be differently prescribed between the two main forms of 
diabetes
•	 There	 are	 also	 many	 other	 factors	 that	 would	 impact	 HbA1c	
spread and outcome
• We have assumed that distributions are broadly normal, so that 
two standard deviations would cover just over 95% of blood 
 glucose results.
2.1 | Statistics
Data were aggregated from the various downloaded CSV data files 
using	Excel	2016	64bit	Power	Pivot	and	aggregated	data	were	sta-
tistically	analysed	using	Analyse-	it	add-	in.
3  | RESULTS
3.1 | Selection of practices
Figure 1 shows the selection of practice years included into the 
study. There are around 7500 GP practices in England that provide 
data	for	the	Quality	&	Outcomes	framework	(QOF)	each	year.	So,	in	
the 3 years selected, there is a total of 23 319 practice years of data 
providing data for 170.7 million total patient years in which there are 
8.7 million patient years of diabetes. Results for Type 1 diabetes are 
required	and	those	are	provided	in	the	NDA	in	which	14	523	practice	
years (62% of total) participated and 66% of diabetes patients and 
total of 447 000 patient years of type 1 were included with an aver-
age of 31 type 1/practice. To avoid small number effects, 1853 prac-
tices	with	≤10	 type	1	patients	were	excluded.	Four	 thousand	 five	
hundred and twenty- four practice years were then included where 
use of BGM strips with accuracy data was >80% of total strips sig-
nificant enough to generate sufficient impact. These practices were 
not significantly different in size or level of diabetes to the other 
practices	excluded.
Out of the total of 70 different types of strips prescribed, only 
20 types were evaluated in accuracy studies selected. These cov-
ered 73% of the total strips prescribed. Figure 2 shows the % of 
total strips used in the period by type and highlights those con-
tained within the accuracy study. The main strips used over this pe-
riod	were	Aviva,	GlucoRx	Nexium,	Mobile,	Contour	Next,	FreeStyle	
F IGURE  2 Overall	cumulative	mix	of	
strip used over 3 years as a percentage of 
total use
0%
1. Aviva (SD = 5.4%)
2. GlucoRx Nexus (SD = 9%)
3. Mobile (SD = 5.3%)
4. Contour Next (SD = 4.6%)
5. FreeStyle Optium (SD = 6.2%)
6. OneTouch Ultra
7. FreeStyle Lite (SD = 6.6%)
8. Contour
9. WaveSense JAZZ (SD = 8.2%)
10. OneTouch Verio (SD = 8.4%)
11. CareSens N
12. TRUEyou (SD = 6.7%)
13. GlucoMen LX Sensor
14. GlucoLab
15. TRUEresult (SD = 5.7%)
16. FreeStyle
17. Mylife Pura (SD = 10.8%)
18. BGStar (SD = 8.2%)
19. Compact
20. Omnitest 3 (SD = 8.8%)
21. Active (SD = 4.2%)
22. GlucoMen GM
23. Element(SD = 13.5%)
24. GlucoMen areo Sensor
25. OneTouch Vita (SD = 9.3%)
26. Microdot+ (SD = 8.1%)
27. iCare Advanced
28. Contour TS
29. SuperCheck 2
30. WaveSense JAZZ Duo
31. TRUEone
32. OneTouch Select Plus (SD = 7.2%)
33. TEE2
34. Performa (SD = 5.5%)
35. Breeze 2
36. GlucoMen Sensor
37. Mylife Unio
38. TrueTrack System
39. Advantage Plus
40. GlucoRx Original (SD = 14.1%)
With accuracy data Without accuracy data
10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
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Optium and OneTouch Ultra which together accounted for 58% of 
BGM strip used in these years.
3.2 | Accuracy and variability at practice level 
(Figure 3)
Practices	prescribe	mixes	of	strips.	By	aggregating	the	number	of	strips	
of each type with % that fall in each band for that strip type, the aver-
age % of strips falling within each band was calculated in each practice.
The accuracy variability was calculated as square root of the 
sum of the percentage of strips in each band times the square 
of the distance of the band from the reference zero. Figure 3 
shows the distribution of strip accuracy within bands, compar-
ing the average of practices in the median decile with those the 
top and bottom deciles when ranked by accuracy variability. The 
average variability of BGMS in the highest variability decile was 
8.2% compared with 5.2% in the lowest decile. In practices with 
highest accuracy/lowest variability (Brown) over 66% of BGMS, 
blood	glucose	results	could	be	expected	to	be	within	5%	of	the	
reference value while those with the lowest accuracy/highest 
variability	 (Green)	 this	 would	 be	 below	 50%.	 At	 the	 other	 end	
in practices with highest accuracy/lowest variability (Brown) less 
than	 3%	 of	 strips,	 results	 could	 be	 expecting	 to	 be	 more	 than	
15% of the reference value while those with the lowest accuracy/
highest variability (Green) this would be above 10%.
3.3 | Glycaemic control variability at practice level 
(Figure 4)
The	NDA	HbA1c	published	values	have	been	reworked	to	show	%	of	
patients’	 results	 in	 each	 practice	 in	 each	 of	 four	 bands	 (<46,	 46-	58,	
58- 86, >86). From this, an estimated mean and variability (square root 
of the sum of the % in each band times square of the difference from 
that mean) were calculated for each practice. The practices were then 
ranked by variability. The median decile with 15% of results >86 mmol/
mol	(10%)	had	a	calculated	mean	HbA1c	of	68.6	mmol/mol	(8.3%)	and	
a	calculated	variability	(HbA1cV)	around	that	mean	of	12.9	mmol/mol	
which is 19% of mean. The average variability for practices in the decile 
with	highest	HbA1c	variability	was	23%	of	the	mean	value,	while	those	
with	lowest	variability	had	a	calculated	variability	(HbA1cV)	of	14%	of	
mean value. GP Practices in the highest variability decile (Green) have 
patients	with	wider	spread	of	HbA1c	results	than	those	in	the	lowest	
spread decile (Brown).
3.4 | Regression modelling for the relation between 
strip accuracy and HbA1C (Figure 5)
The relation between the practice values for BGMS variability and 
HbA1c	 was	 determined.	 Outcome	 variability	 as	 %	 of	 the	 mean	
HBA1c	 was	 calculated.	 The	 regression	 line	 between	 BGMS	 vari-
ability	and	%HbA1c	variability	with	the	points	plotted	showing	the	
actual average of the deciles of GP practices sorted by BGMS vari-
ability. The slope of the regression line is 0.176. Thus, the spread of 
HbA1C	values	for	T1DM	patients	at	the	GP	practice	was	greater	for	
the practices using less precise BGMS.
Applying	the	figure	17.3	(to	convert	HbA1c	variability	into	blood	
glucose variability, modelled on three tests/day over 13 weeks (300 
samples), the increase in blood glucose variability would be three 
times higher than the corresponding BGMS variety.
Applying	the	above	findings	to	the	BGMS	strips	currently	being	used	
(Table 3), we would see those conforming to the current ISO stan-
dard which require 95% of results to be within 15% delivering for an 
expected	meter	reading	of	10	mmol/L	one	result	in	20	ie,	1/week	the	
actual	blood	glucose	levels	more	than	2.7	mmol/L.	If	this	was	applied	
to current best in class strips where 95% of results are within 7.5%, 
then the outcome in blood glucose control would be significantly im-
proved with in comparison, 1/week the actual blood glucose levels 
being	more	than	1.4	mmol/L.
F IGURE  3 BGMS variability vs % 
of BG results within specified bands in 
relation to the reference BG value for 
ranked by their BGM strip variability 
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4  | DISCUSSION
People with T1DM have much greater variation in blood glucose 
with	levels	both	higher	and	lower	readings	than	would	be	expected	
in a person without the condition. These variations derive from the 
mix	of	day-	to-	day	 living	and	 the	 interventions	 that	people	are	uti-
lising. The aim of all therapeutic interventions should be to control 
both the overall average blood glucose and the range of variation of 
blood glucose.
We have identified one potential source of variation as the accu-
racy of the testing strips that patients use multiple times each day 
to adjust titration of their therapy. The variation in BG is three times 
that of the BGMS.
The key finding of our analysis is the linear relation between GP 
practice level prescribed strip accuracy (greater percentage of read-
ings within 10% of the reference laboratory blood glucose) and less 
variability	 in	HbA1C	for	T1DM	individuals.	This	has	significant	 im-
plications	for	achieved	HbA1c	and	therefore	the	longer	term	health	
prospects of people with T1DM.10,11
With the caveat that BGM strip use includes all prescriptions at 
a GP practice level—that is the BGM strip use at a GP practice level 
is quantified for all diabetes patients, not just the T1DM patients—
these real- world findings at a GP practice level accord with the in 
silico findings previously reported by Breton and Kovatchev.1
Based on these findings, we determined that the difference in the 
spread of BGMS variability across GP practices depending on their 
F IGURE  4 HbA1c	variability:	
distribution	of	HbA1c	results	within	GP	
practices in highest, median and lowest 
deciles	of	HbA1c	variability	for	each	
HbA1c	band
0
10
20
30
40
50
60
70
80
HbA1c <48
mmol/mol
 HbA1c 48-58
mmol/mol
HbA1c 58-86
mmol/mol
HbA1c >86
mmol/mol
%
 o
f R
es
ul
ts
 
Highest variability decile (Mean = 66.9 mmol/mol; 
Variability = 15.3 mmol/mol = 23% of mean)
Median variability decile (Mean = 68.6 mmol/mol;
Variability = 12.9 mmol/mol = 19% of mean)
Lowest variability decile (Mean = 71 mmol/mol;
Variability = 9.8 mmol/mol = 14% of mean)
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profile of strip type use, between the top and bottom decile of 2.9% is 
associated	with	an	increase	in	HbA1c	variability	of	0.42%	for	the	GP	
practices. This would correspond when adjusted for sample frequency 
to a variability of blood glucose of 7%. This compares very closely to 
the predicted Blood Glucose variability of 6% for a 2.5% change in 
meter standard deviation taken from the Breton model.1
The clinical corollary of our analysis is that for an individual with 
T1DM	with	blood	glucose	at	10	mmol/L	using	ISO	standard	BGMS,	
on 1/20 occasions (average 1/week) the actual blood glucose value 
could be >±4.5 mmol/l from target, compared with the best perform-
ing BGMS with BG >±2.2 mmol/l from reference on 1/20 occasions.
Poor blood glucose monitoring strip accuracy has been shown 
to induce loss of patient confidence in hour- to- hour and day- to- day 
blood glucose monitoring4,5 and increase the potential increased risk 
of hypoglycaemia12 to which is now added the cumulative damage 
of	running	a	higher	HbA1C	over	time.10 Reduction in the proportion 
of	high	outlying	patients	in	terms	of	HbA1C	would	have	significant	
benefit to people with diabetes in terms of reduced short- term hy-
poglycaemia13 and long- term complication rates.
Investing in improved accuracy of BGMS, can be offset against 
the	benefits	of	 less	variability	 in	HbA1C	values	 in	 the	 longer	 term	
and we would speculate, potentially less patients suffering untoward 
hypoglycaemia because of measurement inaccuracy.
In	 2015-	2016,	 in	 the	 English	 NHS	 spent	 £170	 million	 on	 BGM	
strips.14 Thus, a very large amount of investment goes into the monitor-
ing of blood glucose. Clearly, it is important that the benefits of such a 
large	investment	are	maximised.	A	recent	very	important	development	
for glycaemic monitoring in T1DM has been the introduction of the 
continuous	glucose	monitor	(CGM)	FreeStyle	Libre	Flash	blood	glucose	
monitoring device.15 This has been very well received by patients. It was 
recently demonstrated with in silico modelling that BGM accuracy, and 
more specifically systematic positive or negative bias, has a significant ef-
fect	on	clinical	performance	(HbA1c	and	severe	hypoglycaemia	events.16
The limitations of this study include the fact that we do not have all 
the specifications of the BGM devices nor are all practices in England 
included. Nevertheless, the 4650 GP practices included are very simi-
lar	in	terms	of	T1DM	patients’	profile	from	the	remainder	of	GP	prac-
tices.	A	strength	of	the	study	is	that	it	utilises	national	scale	data.
5  | CONCLUSION
We have determined that at GP practice level prescribing BGM strips 
with	lower	accuracy	is	associated	with	a	greater	spread	of	HbA1C	in	
the people with T1DM attending that practice. In the short term, this 
will contribute to unstable glycaemia including more hypoglycaemia 
for T1DM individuals and in the longer term may increase the devel-
opment of diabetes complications. Our  results suggest there are clear 
advantages to utilising best in class accuracy BGMS. The health eco-
nomic cost of this will be the  subject of a subsequent paper.
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